- Home
- ULS vs ROIV Comparison
ULS vs ROIV Comparison
Compare ULS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULS
- ROIV
- Stock Information
- Founded
- ULS 1894
- ROIV 2014
- Country
- ULS United States
- ROIV United Kingdom
- Employees
- ULS N/A
- ROIV 750
- Industry
- ULS
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ULS
- ROIV Health Care
- Exchange
- ULS Nasdaq
- ROIV Nasdaq
- Market Cap
- ULS 17.2B
- ROIV 14.1B
- IPO Year
- ULS 2024
- ROIV N/A
- Fundamental
- Price
- ULS $88.78
- ROIV $20.62
- Analyst Decision
- ULS Hold
- ROIV Strong Buy
- Analyst Count
- ULS 8
- ROIV 8
- Target Price
- ULS $78.75
- ROIV $21.19
- AVG Volume (30 Days)
- ULS 583.2K
- ROIV 8.4M
- Earning Date
- ULS 11-04-2025
- ROIV 11-10-2025
- Dividend Yield
- ULS 0.60%
- ROIV N/A
- EPS Growth
- ULS 10.58
- ROIV N/A
- EPS
- ULS 1.67
- ROIV N/A
- Revenue
- ULS $3,003,000,000.00
- ROIV $20,329,000.00
- Revenue This Year
- ULS $6.79
- ROIV N/A
- Revenue Next Year
- ULS $6.23
- ROIV $320.50
- P/E Ratio
- ULS $52.16
- ROIV N/A
- Revenue Growth
- ULS 6.68
- ROIV N/A
- 52 Week Low
- ULS $48.54
- ROIV $8.73
- 52 Week High
- ULS $91.95
- ROIV $21.35
- Technical
- Relative Strength Index (RSI)
- ULS 66.37
- ROIV 66.12
- Support Level
- ULS $84.23
- ROIV $19.99
- Resistance Level
- ULS $88.27
- ROIV $20.99
- Average True Range (ATR)
- ULS 2.29
- ROIV 0.74
- MACD
- ULS -0.27
- ROIV -0.20
- Stochastic Oscillator
- ULS 93.32
- ROIV 52.88
About ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.